Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 18 to 80 years inclusive at the time of informed consent~* Subjects must have non-malignant chronic pain treated with opioids and must have opioid-induced constipation (OIC)~* Subjects must be treated with a stable opioid regimen at a total daily dose on average of ≥ 30 mg equivalents of oral morphine sulfate~* Subjects must not be currently using laxatives or must be willing to discontinue laxative use at Screening and must be willing to use only the rescue laxatives provided throughout the study duration~* Subjects must meet opioid-induced constipation criteria based on the Bowel Movement and Constipation Assessment (BMCA) Diary~Exclusion Criteria:~* Evidence of significant structural abnormalities of the gastrointestinal (GI) tract~* Evidence of active medical diseases affecting bowel transit~* History or presence of pelvic disorders that may be a cause of constipation~* Surgery (except for minor procedures) within 60 days of Screening~* History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation (e.g., mechanical GI obstruction)~* Subjects who have never taken laxatives for the treatment of OIC~* History of active treatment for cancer within the last 2 years (except for basal cell or squamous cell carcinoma of the skin that have been successfully resected) or tamoxifen \[Nolvadex®\] and raloxifene \[Evista®\] when being used for prevention of breast cancer~* Current use of any prohibited medication including opioid antagonists, partial agonists, or mixed agonists/antagonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Naldemedine (Type: EXPERIMENTAL): Participants received 0.2 mg naldemedine orally once daily for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo orally once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).